Exelixis (NASDAQ:EXEL) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Exelixis (NASDAQ:EXEL) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Exelixis (NASDAQ:EXEL – Get Rating) released its earnings results on Tuesday. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04), Briefing.com reports. The company had revenue of $423.92 million for the quarter, compared to the consensus estimate of $418.71 million. Exelixis had a return on equity of 13.11% and a net margin of 18.78%. The business's revenue was down 6.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.29 EPS.
Exelixis(纳斯达克：Exel-Get Rating)周二发布了财报。据Briefing.com报道，这家生物技术公司公布了本季度每股收益(EPS)(0.09美元)，低于(0.04美元)(0.05美元)的普遍预期。该公司本季度营收为4.2392亿美元，而市场普遍预期为4.1871亿美元。Exelixis的股本回报率为13.11%，净利润率为18.78%。该业务的收入同比下降了6.0%。去年同期，该公司公布的每股收益为0.29美元。
Exelixis Price Performance
Exelixis性价比
NASDAQ:EXEL traded up $0.53 during mid-day trading on Wednesday, reaching $17.82. The stock had a trading volume of 1,101,195 shares, compared to its average volume of 2,793,073. Exelixis has a 12 month low of $14.87 and a 12 month high of $23.40. The stock has a market capitalization of $5.75 billion, a PE ratio of 18.53, a P/E/G ratio of 0.58 and a beta of 0.72. The stock has a 50-day simple moving average of $16.60 and a two-hundred day simple moving average of $17.26.
纳斯达克：周三午盘交易中，Exel上涨0.53美元，至17.82美元。该股成交量为1,101,195股，而平均成交量为2,793,073股。Exelixis的12个月低点为14.87美元，12个月高位为23.40美元。该股市值57.5亿美元，市盈率18.53倍，市盈率0.58倍，贝塔系数0.72。该股的50日简单移动均线切入位为16.60美元，200日简单移动均线切入位为17.26美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
A number of brokerages recently weighed in on EXEL. Royal Bank of Canada lowered their target price on shares of Exelixis from $31.00 to $29.00 and set an "outperform" rating on the stock in a report on Wednesday, November 2nd. Piper Sandler reaffirmed an "overweight" rating and issued a $32.00 price objective on shares of Exelixis in a research report on Wednesday. EF Hutton Acquisition Co. I reissued a "buy" rating and set a $24.00 target price on shares of Exelixis in a report on Wednesday. Credit Suisse Group started coverage on shares of Exelixis in a research note on Thursday, January 26th. They issued an "outperform" rating and a $29.00 price target on the stock. Finally, Cowen decreased their price objective on Exelixis from $21.00 to $20.00 in a report on Monday, January 9th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $27.58.
一些券商最近加入了对Exel的看法。11月2日周三，加拿大皇家银行在一份报告中将Exelixis的目标价从31.00美元下调至29.00美元，并对该股设定了“跑赢大盘”的评级。派珀·桑德勒在周三的一份研究报告中重申了对Exelixis的“增持”评级，并对Exelixis的股票发布了32.00美元的目标价。EF Hutton Acquisition Co.I在周三的一份报告中重新发布了买入评级，并为Exelixis的股票设定了24.00美元的目标价。瑞士信贷集团在1月26日星期四的一份研究报告中开始对Exelixis的股票进行报道。他们对该股给予了“跑赢大盘”的评级和29.00美元的目标价。最后，考恩在1月9日星期一的一份报告中将Exelixis的目标价格从21.00美元下调至20.00美元。一名投资分析师对该股的评级为持有，九名分析师给予该股买入评级。根据MarketBeat的数据，该公司的共识评级为“适度买入”，共识目标价为27.58美元。
Insiders Place Their Bets
内部人士下注
Institutional Inflows and Outflows
机构资金流入和流出
A number of institutional investors have recently modified their holdings of EXEL. Toroso Investments LLC bought a new stake in shares of Exelixis in the third quarter valued at $198,000. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Exelixis in the third quarter worth $672,000. Captrust Financial Advisors boosted its stake in Exelixis by 167.4% during the third quarter. Captrust Financial Advisors now owns 15,766 shares of the biotechnology company's stock valued at $247,000 after buying an additional 9,871 shares during the period. Balyasny Asset Management LLC purchased a new position in Exelixis during the third quarter worth about $6,672,000. Finally, BNP Paribas Arbitrage SNC increased its stake in Exelixis by 17.0% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 214,537 shares of the biotechnology company's stock worth $3,364,000 after acquiring an additional 31,114 shares during the last quarter. Institutional investors and hedge funds own 84.74% of the company's stock.
一些机构投资者最近调整了对Exel的持股。Toroso Investments LLC在第三季度购买了Exelixis的新股份，价值19.8万美元。肯塔基州教师退休系统在第三季度购买了价值672,000美元的Exelixis新股。CapTrust Financial Advisors在第三季度将其在Exelixis的持股增加了167.4%。CapTrust Financial Advisors现在拥有这家生物技术公司15,766股股票，价值24.7万美元，在此期间又购买了9,871股。Balyasny Asset Management LLC在第三季度购买了Exelixis的一个新头寸，价值约6,672,000美元。最后，法国巴黎银行套利SNC在第三季度将其在Exelixis的持股增加了17.0%。法国巴黎银行套利SNC现在持有这家生物技术公司214,537股票，价值336.4万美元，在上个季度额外购买了31,114股票。机构投资者和对冲基金持有该公司84.74%的股票。
About Exelixis
关于Exelixis
(Get Rating)
(获取评级)
Exelixis, Inc is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B.
Exelixis，Inc.是一家生物制药公司，致力于癌症治疗新药的开发、商业化和发现。它提供COMETRIQ、CABOMETYX、COTELLIC和MINNEBRO品牌的产品。该公司是由科里·S·古德曼和斯特利奥斯·B。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Exelixis (EXEL)
- TJX Among Apparel Retailers All Dressed Up & Ready For Growth
- Daqo New Energy Charged Up For New Highs
- No Spice In Chipotle Results, Is Now The Time To Buy?
- V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
- Fortinet's Earnings Rally is a Lesson in Market Expectations
- 免费获取StockNews.com关于Exelixis的研究报告(Exel)
- 服装零售商中的TJX都盛装打扮，为增长做好了准备
- 大全新能源再创新高
- Chipotle结果中没有香料，现在是买入的时候了吗？
- 尽管削减了股息，V.F.Corporation仍是一笔高收益的交易
- Fortinet的盈利上涨是市场预期的教训
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Exelixis日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Exelixis和相关公司的最新新闻和分析师评级的每日简要摘要。